Hoffmann-la Roche Inc.

Roche Glycart Ag

Roche Palo Alto LLC

F. Hoffmann-la Roche Ag

Johannes Auer

Christian Klein

Ekkehard Moessner

Pablo Umana

Guy Georges

Stefan Seeber

Martin Bader

Stefan Lorenz

Birgit Bossenmaier

Stefan Dengl

Jens Fischer

Gerhard Niederfellner

Alexander Lifke

Wolfgang Schaefer

Ulrich Brinkmann

Peter Bruenker

Hubert Kettenberger

Michael Brandt

Joerg Moelleken

Stefan Klostermann

Nikolaos Dimoudis

Christian Schantz

Hendrik Knoetgen

Apollon Papadimitriou

Maximiliane Koenig

Wilma Lau

Petra Hanke

Claire Louise Langrish

Claudio Sustmann

Herein is reported a method for the humanization of non-human antibodies using a structure-based scoring matrix. With the scoring matrix it is possible to determine (the requirement for and) the suitability of specific (back)mutations of amino acid residues at defined positions of a selected human germline sequence. The scoring matrix takes into account the topology, the three-dimensional structure and the interactions of the respective residue and change. Thereby the influence on antigen binding of a specific amino acid residue change can be determined.

Three-dimensional structure-based humanization method

The invention provides anti-BRDU antibodies and methods of using the same.

Anti-BRDU antibodies and methods of use

Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (B-CS-I-CS-FC-CS-I-CS-B), wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.

Method for producing monomeric and multimeric molecules and uses thereof

Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (B-CS-I-CS-FC-CS-ICS-B), wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.

Bispecific tetravalent antibodies against IL-17 and TNFa, useful in therapy, e.g. the treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions.

TNFa-IL-17 bispecific antibodies

The present invention relates to Bispecific antibodies against human TWEAK and human IL17 (bispecific TWEAK-IL17 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antibodies against human TWEAK and human IL17 and uses thereof

The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Humanized anti-CDCP1 antibodies

An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between C1 and C2 and/or in the second inter-domain region at amino acid position 327-331 between C2 and C3 has advantageous properties for the treatment of inflammatory diseases.

Antibodies against human IL17 and uses thereof

A method for the production of the &#x3b1;-chain of hepatocyte growth factor or an N-terminal fragment thereof (NK polypeptide) by expression of a nucleic acid encoding said NK polypeptide in a microbial host cell, isolating inclusion bodies containing said NK polypeptide in denatured form, solubilization of the inclusion bodies and naturation of the denatured NK polypeptide, which is characterized in that in said nucleic acid at least one of the codons of amino acids selected from the group consisting of codons at positions 33, 35 and 36 is CGT, results in an improved expression yield.

Method for the recombinant expression of an N-terminal fragment of hepatocyte growth factor

Growing community of inventors

Schwaigen, Germany

Johannes Auer